Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients
Journal article, 2021
The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.
nucleoprotein‐specific antibodies
COVID‐19
endemic coronaviruses
disease severity
Author
Susannah Leach
University of Gothenburg
Sahlgrenska University Hospital
Ali M. Harandi
University of Gothenburg
University of British Columbia (UBC)
Tomas Bergstrom
University of Gothenburg
Lars-Magnus Andersson
University of Gothenburg
Sahlgrenska University Hospital
Staffan Nilsson
University of Gothenburg
Chalmers, Mathematical Sciences, Applied Mathematics and Statistics
Lia van der Hoek
University of Amsterdam
Magnus Gisslen
University of Gothenburg
Sahlgrenska University Hospital
Journal of Medical Virology
0146-6615 (ISSN) 1096-9071 (eISSN)
Vol. 93 9 5614-5617Subject Categories
Infectious Medicine
Gastroenterology and Hepatology
Rheumatology and Autoimmunity
DOI
10.1002/jmv.27038
PubMed
33913546